Published in Nanotechnology on September 16, 2010
Noble metal nanoparticles for biosensing applications. Sensors (Basel) (2012) 1.44
Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium. Indian J Med Res (2013) 1.01
Emerging technologies for monitoring drug-resistant tuberculosis at the point-of-care. Adv Drug Deliv Rev (2014) 0.93
Isothermal DNA amplification coupled to Au-nanoprobes for detection of mutations associated to Rifampicin resistance in Mycobacterium tuberculosis. J Nanobiotechnology (2013) 0.86
One nanoprobe, two pathogens: gold nanoprobes multiplexing for point-of-care. J Nanobiotechnology (2015) 0.80
AuNPs for identification of molecular signatures of resistance. Front Microbiol (2014) 0.79
Accurate Detection of Rifampicin-Resistant Mycobacterium Tuberculosis Strains. Sensors (Basel) (2016) 0.77
Colorimetric Assay for Exon 7 SMN1/SMN2 Single Nucleotide Polymorphism Using Gold Nanoprobes. Bioimpacts (2013) 0.75
Antibiotic stress, genetic response and altered permeability of E. coli. PLoS One (2007) 1.50
Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One (2012) 1.46
Noble metal nanoparticles for biosensing applications. Sensors (Basel) (2012) 1.44
Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2002) 1.30
Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2003) 1.30
Molecular characterization of methicillin-resistant Staphylococcus epidermidis clones: evidence of geographic dissemination. J Clin Microbiol (2002) 1.26
Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol (2011) 1.22
Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother (2007) 1.19
New insights into the use of magnetic force microscopy to discriminate between magnetic and nonmagnetic nanoparticles. Nanotechnology (2010) 1.12
Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. ACS Nano (2012) 1.10
Gold-nanoparticle-probe-based assay for rapid and direct detection of Mycobacterium tuberculosis DNA in clinical samples. Clin Chem (2006) 1.08
Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. Int J Antimicrob Agents (2008) 1.07
Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance. BMC Microbiol (2011) 1.06
Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. J Biol Eng (2009) 1.05
Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents (2008) 1.04
Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol (2011) 1.04
Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide. J Antimicrob Chemother (2008) 1.04
Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother (2009) 1.01
Gold and silver nanoparticles for clinical diagnostics - From genomics to proteomics. J Proteomics (2011) 1.01
Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events. Biomaterials (2013) 1.00
High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother (2013) 1.00
Gold-nanobeacons for gene therapy: evaluation of genotoxicity, cell toxicity and proteome profiling analysis. Nanotoxicology (2013) 0.99
The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo (2007) 0.98
Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J Antimicrob Chemother (2008) 0.98
Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus. Int J Antimicrob Agents (2002) 0.97
Gold on paper-paper platform for Au-nanoprobe TB detection. Lab Chip (2012) 0.97
The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. Int J Antimicrob Agents (2009) 0.96
Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist (2008) 0.96
In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials (2013) 0.95
Multidrug Efflux Pumps in Staphylococcus aureus: an Update. Open Microbiol J (2013) 0.95
Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. Methods Mol Biol (2010) 0.94
Antimicrobial activity of phenothiazines. In Vivo (2005) 0.94
Genetic characterisation of the ethambutol resistance-determining region in Mycobacterium tuberculosis: prevalence and significance of embB306 mutations. Int J Antimicrob Agents (2008) 0.94
An instrument-free method for the demonstration of efflux pump activity of bacteria. In Vivo (2006) 0.94
The vitamin B1 metabolism of Staphylococcus aureus is controlled at enzymatic and transcriptional levels. PLoS One (2009) 0.92
Review. Comparison of multidrug resistant efflux pumps of cancer and bacterial cells with respect to the same inhibitory agents. In Vivo (2007) 0.92
Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev Anti Infect Ther (2012) 0.91
Identification of efflux pump-mediated multidrug-resistant bacteria by the ethidium bromide-agar cartwheel method. In Vivo (2011) 0.91
Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. In Vivo (2010) 0.91
Biological activity of twenty-three hydantoin derivatives on intrinsic efflux pump system of Salmonella enterica serovar Enteritidis NCTC 13349. In Vivo (2011) 0.91
Ion sensing (EIS) real-time quantitative monitorization of isothermal DNA amplification. Biosens Bioelectron (2013) 0.90
Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections. Expert Rev Anti Infect Ther (2010) 0.89
Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents (2012) 0.89
Gold-nanobeacons for real-time monitoring of RNA synthesis. Biosens Bioelectron (2012) 0.89
Thioridazine reduces resistance of methicillin-resistant staphylococcus aureus by inhibiting a reserpine-sensitive efflux pump. In Vivo (2006) 0.88
Unraveling Mycobacterium tuberculosis genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting. BMC Genomics (2014) 0.88
Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains. Int J Antimicrob Agents (2010) 0.88
Enhanced detection of tuberculous mycobacteria in animal tissues using a semi-nested probe-based real-time PCR. PLoS One (2013) 0.87
A promising road with challenges: where are gold nanoparticles in translational research? Nanomedicine (Lond) (2014) 0.87
Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant Staphylococcus aureus: an in vivo, ex vivo and electron microscopy study. In Vivo (2005) 0.87
Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea? Front Pharmacol (2013) 0.87
From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition. J Antimicrob Chemother (2012) 0.87
Role of the Mmr efflux pump in drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 0.87
Isothermal DNA amplification coupled to Au-nanoprobes for detection of mutations associated to Rifampicin resistance in Mycobacterium tuberculosis. J Nanobiotechnology (2013) 0.86
Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations. J Infect Chemother (2002) 0.86
RNA quantification using gold nanoprobes - application to cancer diagnostics. J Nanobiotechnology (2010) 0.85
In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int J Antimicrob Agents (2007) 0.84
Gamma delta T cell responses associated with the development of tuberculosis in health care workers. FEMS Immunol Med Microbiol (2005) 0.84
Phenothiazines alter resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro. Int J Antimicrob Agents (2003) 0.84
A rapid and simple method for identifying Mycobacterium tuberculosis W-Beijing strains based on detection of a unique mutation in Rv0927c by PCR-SSCP. Microbes Infect (2009) 0.84
Thioridazine induces apoptosis of multidrug-resistant mouse lymphoma cells transfected with the human ABCB1 and inhibits the expression of P-glycoprotein. Anticancer Res (2011) 0.83
pH Modulation of efflux pump activity of multi-drug resistant Escherichia coli: protection during its passage and eventual colonization of the colon. PLoS One (2009) 0.83
Ethidium bromide efflux by Salmonella: modulation by metabolic energy, pH, ions and phenothiazines. Int J Antimicrob Agents (2011) 0.83
Anti-cancer precision theranostics: a focus on multifunctional gold nanoparticles. Expert Rev Mol Diagn (2014) 0.83
Identification of efflux-mediated multi-drug resistance in bacterial clinical isolates by two simple methods. Methods Mol Biol (2010) 0.83